beta amyloid

An Australian research project has found a way to bring forward the detection of early stage Alzheimer's disease by up to 18 months.

Alzheimer’s disease is characterized by very high levels of a molecule called beta-amyloid in the brain.

A promising vaccine being tested for Alzheimer's disease does what it is designed to do -- clear beta-amyloid plaques from the brain -- but it does not seem to help restore lost learning and memory abilities, according to a new study.

A groundbreaking study in the journal Brain confirms that Pittsburgh Compound-B binds to the telltale beta-amyloid deposits found in the brains of patients with Alzheimer's disease.

The finding is a significant step toward enabling clinicians to provide a definitive diagnosis of Alzheimer's disease in living patients.